Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

COMPARE StudyThe COMPARE study is a physician-initiated "all-comers" trial sponsored by Maasstad Ziekenhuis of Rotterdam, the Netherlands. The study, designed to reflect real-world, everyday clinical practice, enrolled 1,800 patients in a single- center, prospective randomized (1:1) comparison of safety and efficacy of the XIENCE V™ Everolimus Eluting Stent System to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System.  The COMPARE trial was supported in part by an Abbott grant.  All aspects of the trial were designed and conducted independent of Abbott.

About XIENCE VAbbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe, Japan and other international markets.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott VascularAbbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.<
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Research and Markets  has announced the addition of ... report to their offering. Intranasal drug delivery ... of drugs for the treatment of local diseases in ... non-allergic rhinitis and sinusitis. The nose is considered to ... systematic drug delivery. Continuous technological advancement ...
(Date:8/26/2014)... , Aug. 26, 2014   Quanta Aesthetic Lasers , ... North America , expands the offerings in their robust ... which is now available for shipping to medical spas, clinics, ... . The QuantaShape is manufactured in the Chianti ... General Project .  The device was previously sold as both ...
(Date:8/26/2014)...  When it comes to diabetes supplies, innovations are often ... happens to answer a real medical need. ... market, Timesulin shows how long it,s been since your ... or double insulin doses. Very easy to use, Timesulin ... insulin pen after an injection. There is no settings ...
Breaking Medicine Technology:Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3Another Italian Beauty Joins the Quanta Aesthetic Lasers Lineup 2Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2
... Popular antidepressants taken with tamoxifen can increase the risk ... May 30 A new study found that taking ... of breast cancer recurrence in women taking both medications. ... work effectively.(Logo: http://www.newscom.com/cgi-bin/prnh/20090530/DC24767LOGO ) ...
... Abstract # 25670ORLANDO, Fla., May 29 ... has selected new breast cancer research conducted ... in Detroit for posting on ASCO,s Web ... promising new therapeutic target for aggressive hormone ...
Cached Medicine Technology:New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 2Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 3
(Date:8/27/2014)... A recent University College London (UCL) ... the dental community disagrees on the best way to ... of dental advice suggested that some six different tooth-brushing ... more popular than the rest. , “The easiest ... floss your teeth regularly,” said Dr. Alexandre-Amir Aalam, DDS, ...
(Date:8/27/2014)... "It can be quite difficult to wipe one’s ... inventor from Lehigh Acres, Fla.," so I designed an ... task." He then created a prototype of his idea. ... to wipe and clean the behind thoroughly after going ... well as prevents direct contact with waste or anal ...
(Date:8/27/2014)... Neil Haley, the Total Tutor host of the ... out about the importance of capacity to grow a business. ... ViSalus and is now a 5 Star Ambassador, Vi Millionaire, ... book titled "The Playful and Powerful Warrior Within You!" and ... working out for over 1000 days straight. He is ...
(Date:8/27/2014)... City, Utah (PRWEB) August 27, 2014 ... advancing the business of healthcare, is pleased to ... a ground-breaking online recruitment resource specifically designed for ... is undergoing significant changes. To help address the ... workforce, and tighter budgets—AAPC launched CareerHealth.com . ...
(Date:8/27/2014)... IntelliSoft Group, LLC, a leading provider of credentialing, ... IntelliCred, IntelliApp and IntelliContract Version 14.2 at ... Annual Conference on September 16, 2014 at the SERESC ... improvements available in IntelliSoft’s Version 14.2 healthcare ... A new Contract Connection Tab connects the healthcare provider ...
Breaking Medicine News(10 mins):Health News:Americans Confused About How to Brush Teeth 2Health News:InventHelp Client's Device Helps a User Wipe Thoroughly After Going to the Bathroom (HLW-1300) 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 3Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 2Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 3Health News:IntelliSoft Group to Unveil Version 14.2 of IntelliCred, IntelliApp and IntelliContract at the New Hampshire Association of Medical Staff Services Annual Conference 2
... pressure as it has been urged to make emergency contraception ... Eschenbach, acting Commissioner of the FDA has been urged to ... to sell its morning after pill or Plan B without ... set of two pills that can prevent pregnancy if taken ...
... arrested for allegedly selling fake question papers of the Combined ... 17 districts in the state today, police said. ... held here for selling CPMT question papers, which later turned ... of K G Dental University, which organised the CPMT examinations ...
... drugs seem to hold many youth under a spell. Recent ... to the tune of an increase of 400%, ever since ... reiterated the need for specialized services to remedy this menace, ... the University of Glasgow, said: "These figures are shocking and ...
... is to be conducted among children in the age group ... the kids are following proper eating habits// and there by ... mainly to tackle the worsening health crisis. But the Children's ... the child’s parents about the test results would stigmatize some ...
... is the second most deadly cancer among women. Statistics reveals ... result of cervical cancer. Hence researchers were keen on finding ... way to the development of a vaccine with the potential ... cervical cancer. ,It is mainly caused by ...
... conducted at New York indicates that people suffering from symptomatic ... C// and manganese than their counterparts without the problem. ... Dr N. J. Wareham et al of Medical Research Council ... reduce the onset of asthma. ,This study revealed ...
Cached Medicine News:
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... Nellcor's most popular handheld oximeter has ... Oximetry platform and is now compatible with ... including the MAX-FAST Forehead Sensor and SoftCare ... Pulse Oximeter also incorporates Nellcor's latest advanced ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: